Medtronic’s Drug-Coated Balloon Impresses In Peripheral Artery Trial
This article was originally published in The Gray Sheet
Executive Summary
Medtronic may have gained an edge over C.R. Bard in the future U.S. drug-coated balloon market as one-year results of a randomized trial of its IN.PACT Admiral paclitaxel-coated peripheral angioplasty balloon appear to be the best yet for a peripheral intervention device.
You may also be interested in...
Medtronic, Bard In Close Race To First FDA-Approved Drug-Eluting Balloon
Medtronic says it reached the necessary trial enrollment to support PMA approval for its IN.PACT Admiral drug-eluting balloon catheter to treat atherosclerosis in the superficial femoral artery. On the same day, CR Bard said it was prepared to submit its final PMA module for its Lutonix drug-eluting balloon by year’s end.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.